Nov 19,2024

Cognito Therapeutics Presents Early-Stage Cost-Effectiveness Analysis of Spectris™ Therapy in Alzheimer’s Disease at ISPOR 2024

Cognito Therapeutics presented an early-stage cost-effectiveness analysis of its Spectris™ therapy for Alzheimer’s disease (AD) at the ISPOR Europe 2024 Annual Meeting. The analysis, based on data from the Phase II OVERTURE study, highlighted Spectris as a potentially cost-effective, non-invasive treatment option for AD. The therapy, which uses visual and auditory stimulation to improve brain function, demonstrated a 77% reduction in functional decline compared to a placebo group. The model showed that Spectris could be economically viable at an acquisition cost between $44,000 and $108,000, offering potential savings by reducing long-term care costs and improving patient outcomes. Cognito’s ongoing HOPE trial will provide further data to support Spectris's role in AD treatment.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Nov 11,2024

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-driven precision medicine, announced the publication of its study in JAMA Network Open, titled "Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer (NSCLC)." The study, which analyzed over 5,500 NSCLC patients, found that combining RNA and DNA next-generation sequencing (NGS) detected more actionable structural variants than DNA sequencing alone. This dual approach identified 15.3% more patients with actionable variants, highlighting the value of concurrent RNA and DNA testing for improving clinical outcomes and personalized treatment options in cancer care.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Nov 04,2024

LATE-BREAKING DATA SHOWS SUSTAINED BENEFITS OF ABBOTT'S ESPRIT™ BTK SYSTEM FOR PEOPLE BATTLING PERIPHERAL ARTERY DISEASE BELOW THE KNEE

Abbott announced two-year results from its LIFE-BTK clinical trial, showing strong outcomes for its Esprit™ BTK Everolimus Eluting Resorbable Scaffold System, an FDA-approved dissolvable stent designed to treat severe peripheral artery disease (PAD) below the knee. The data demonstrated that 90.3% of patients treated with the Esprit BTK System did not require repeat procedures at 24 months, showing greater durability and reduced re-closure rates compared to traditional balloon angioplasty. The trial, presented at VIVA 2024, underscores Esprit BTK’s potential to reduce severe complications and improve quality of life for PAD patients. Abbott also launched a Post-Approval Study to further evaluate the system’s safety and effectiveness.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
May 30,2024

Economic Savings Model for Omada’s Cardiometabolic Programs

Using a Markov model, this study estimated the reduction of disease onset and associated cost savings for Omada’s cardiometabolic programs. Estimated gross savings in medical expenditures across the programs in 2022 dollars were $892 to $1,342 after 1 year, and cumulative estimated gross medical savings were $2,963 to $4,346 after 3 years and $5,221 to $7,756 after 5 years.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Oct 01,2024

Clinical Use of Mental Health Digital Therapeutics in a Large Health Care Delivery System: Retrospective Patient Cohort Study and Provider Survey

A study examining digital therapeutics (DTx) in mental health found that 16% of patients received DTx recommendations, primarily younger, female, and of Asian or Hispanic descent, with fewer medical comorbidities. Patients recommended for DTx had lower depression and anxiety scores but higher severe symptom levels among females. A survey of mental health providers revealed that nonprescribers were more likely to recommend DTx than prescribers, with only 29.4% using electronic health record tools for recommendations. Overall, DTx integration into treatment was limited, and providers often viewed it as a supplementary strategy rather than a core treatment component.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Sep 05,2024

Utilizing Continuous Glucose Monitoring for Early Detection of Gestational Diabetes Mellitus and Pregnancy Outcomes in an Asian Population

A study of 103 overweight or obese Asian women in early pregnancy found that continuous glucose monitoring (CGM) may effectively predict gestational diabetes mellitus (GDM) and adverse pregnancy outcomes, such as primary cesarean delivery and larger-than-average newborns. CGM-derived metrics outperformed traditional risk models in predicting GDM, suggesting that CGM could be valuable in early pregnancy screenings to improve outcomes for high-risk pregnancies.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 26,2024

Mobile phone interventions to improve health outcomes among patients with chronic diseases: an umbrella review and evidence synthesis from 34 meta-analyses

An umbrella review analyzed 34 meta-analyses from 235 randomized controlled trials across 52 countries, involving nearly 49,000 participants with ten chronic conditions, to assess the effectiveness of mobile phone interventions. The findings revealed that mobile apps significantly reduced glycated hemoglobin in adults with type 2 diabetes. Text messages and apps also showed strong positive effects on medication adherence in HIV patients and cardiovascular disease management, as well as improvements in glucose management and blood pressure reduction. However, 42% of the analyzed effects were non-significant, highlighting the need for further research. Key gaps identified included limited studies from low-income countries, inadequate reporting of adverse events, and the challenge of inconsistent conclusions across existing reviews. The study underscores the potential of mobile health technology to improve chronic disease management but also calls for enhanced methodological rigor in future research.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 30,2024

Accuracy of Continuous Glucose Monitoring in Hemodialysis Patients With Diabetes

A recent study published in Diabetes Care investigates the accuracy of continuous glucose monitoring (CGM) compared to traditional blood glucose measurements for hemodialysis patients with diabetes. The study, conducted on 31 patients using the Dexcom G6 CGM, found a moderate correlation between CGM and blood glucose readings, with a mean difference of around +15 mg/dL. Although accuracy was lower during hemodialysis, error grids indicated that nearly all CGM readings were within clinically acceptable ranges. The findings highlight the potential for CGM use in this patient group, though further research is needed to confirm its benefits.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 09,2024

Swing Therapeutics Announces The Lancet Publication of Data from Phase 3 Trial of Stanza™ – a Digital Behavioral Therapy for Fibromyalgia Symptoms

Swing Therapeutics announced significant findings from its pivotal Phase 3 trial of Stanza, a self-guided smartphone-based program delivering Acceptance and Commitment Therapy (ACT) for fibromyalgia treatment. Published in The Lancet, the study demonstrated that Stanza significantly improved fibromyalgia-related well-being, pain intensity, fatigue, and depression compared to an active control group, with no adverse effects reported. The trial involved 275 participants and showed that 70.6% of those using Stanza experienced improvement in overall health, compared to 22.2% in the control group. Stanza, which received FDA De Novo marketing authorization in 2023, is available by prescription through Swing Care, a virtual clinic focused on comprehensive fibromyalgia management. This innovative, non-drug therapy aims to make treatment more accessible for patients with fibromyalgia, addressing unmet needs in a condition typically limited to pharmacological options.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jul 09,2024

Kaia Health’s Digital Therapy Shows Sustained Impact on Pain Reduction, Functional Ability, Mental Health, and Cost-Effectiveness in 12-Month Study

Kaia Health's 12-month follow-up results from the Rise-uP study demonstrate significant long-term benefits of its digital therapy for lower back pain. The study, involving over 1,200 participants, showed a 46% reduction in pain intensity, compared to 24% in the control group. Users also experienced improved functional ability, enhanced mental health, and greater satisfaction. Additionally, the digital-first approach led to an 81% reduction in healthcare costs, primarily through fewer hospital visits and lower medication expenses. These findings highlight the effectiveness and cost-efficiency of Kaia’s digital therapy in managing chronic pain.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY